Please check your internet connection and try again.
# MegaCV
## Overview
MegaCV is a brand name for a combination medication containing amlodipine and valsartan. Amlodipine is a dihydropyridine calcium channel blocker, and valsartan is an angiotensin II receptor blocker (ARB).
## Primary Indications
Hypertension. This combination is indicated for the treatment of high blood pressure in patients whose blood pressure is not adequately controlled on either amlodipine or valsartan monotherapy.
## Adult Dosing
The typical starting dose is one tablet daily.
Common strengths are 5mg amlodipine/160mg valsartan, 10mg amlodipine/160mg valsartan, and 5mg amlodipine/320mg valsartan.
The maximum daily dose is 10 mg amlodipine/320 mg valsartan, taken once daily.
## Pediatric Dosing
Data regarding safety and efficacy in pediatric patients is limited. Specific dosing recommendations are not established.
## Dose Adjustments
* **Renal Impairment:** Use with caution in severe renal impairment. No dose adjustment is typically needed in mild to moderate renal impairment, but monitoring is advised.
* **Hepatic Impairment:** Use with caution in patients with hepatic impairment. Amlodipine is slowly metabolized by the liver. Start with lower doses if hepatic impairment is present.
## Contraindications
* Known hypersensitivity to amlodipine, valsartan, or any component of the formulation.
* Concomitant use of aliskiren in patients with diabetes mellitus.
* History of angioedema related to previous ARB therapy.
* Pregnancy (due to the risk of fetal injury or death).
## Adverse Effects
* **Common:** Edema (peripheral), dizziness, headache, fatigue, flushing, nausea, upper respiratory tract infection.
* **Less Common but Serious:** Angioedema, hyperkalemia, hypotension, renal impairment, liver dysfunction.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Increased amlodipine levels with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir). Decreased amlodipine levels with CYP3A4 inducers.
* **Potassium-Sparing Diuretics/Potassium Supplements:** Increased risk of hyperkalemia with ARBs.
* **NSAIDs:** May reduce antihypertensive effect and increase risk of renal impairment.
* **Lithium:** Increased lithium toxicity risk when co-administered with ARBs.
* **Aliskiren:** Increased risk of adverse effects, including hyperkalemia and hypotension, particularly in patients with diabetes.
## Monitoring
* Blood pressure response.
* Renal function (serum creatinine, BUN).
* Electrolytes (serum potassium), especially in patients with renal impairment or those taking potassium-sparing diuretics.
* Signs and symptoms of angioedema.
* Liver function tests may be considered in patients with hepatic impairment.
## Clinical Pearls
* This combination provides a synergistic effect on blood pressure by targeting different mechanisms.
* Edema is a common side effect of amlodipine and may be dose-limiting.
* Monitor for signs of hyperkalemia, especially in patients with renal insufficiency or on potassium-sparing agents.
* Advise patients to avoid salt substitutes containing potassium unless otherwise directed by their healthcare provider.
* Discontinue immediately if angioedema occurs.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for definitive patient care decisions.
